NovoLog® FlexPen®: A dial-a-dose insulin pen that is easy to put in the hands of patients


 

See the benefits of the FlexPen®



 

NovoLog® FlexPen® is the #1-selling pre-filled insulin pen in the world1

aNeedles are sold separately and may require a prescription in some states.
 



 

FlexPen® offers many benefits

  • Teachable, learnable, usable
  • Proven accuracy2
  • Discreet—fits neatly in your patient’s purse or pocket
  • Covered for more than 95% of managed careb patients nationwide3
  • Patients who use FlexPen® may get 50% more insulin with each prescription (1,500 units in a box of 5 pens, compared to 1,000 units in a vial)

bManaged care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change.

 



 

Can be used with NovoTwist® or NovoFine® Needles

NovoTwist®– introducing the first single-twist needle

  • “Just Twist” injection needle with a bayonet fitting
  • Less time-consuming for patients to attach
  • Audible and tactile confirmatory click for correct attachment
  • Available for 30G (8 mm) and 32G Tip (5 mm) needles

NovoFine® Needles

  • NovoFine® needles fit all major insulin devices
  • NovoFine® 32G Tip with SuperFlow™ Technology designed to enhance flow rate and reduce dosing force when injecting
  • Little or no painc - A majority of patients using the NovoFine® 32G Tip needle experienced almost no painc
  • NovoLog® FlexPen® uses NovoFine® disposable needles, designed to help improve injection comfort

Needles are sold separately and may require a prescription in some states. Needles and NovoLog® FlexPen® must not be shared.

cMulticenter, randomized, open-label, 2-period, crossover trial in insulin-treated patients with diabetes (type 1 or type 2). Patients were randomized to self administer insulin injections with one needle type followed by the alternative, each for 7 to 14 days. The 2 needle types used were NovoFine® 32-gauge tip x 6 mm and NovoFine® 30-gauge tip x 8 mm.4
 



 

NovoLog® FlexPen®: stable in storage

dPenFill® cartridges in use (opened) must NOT be stored in the refrigerator.
eVials in use (opened) may be stored in the refrigerator until the label expiration date.

 

Broad Formulary Access

Learn about NovoLog® FlexPen® coverage in your area.


 


 

Related Prescribing Topics:

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

  • Administration: NovoLog® should generally be given immediately (within 5-10 minutes) prior to the start of a meal. Any change of insulin dose should be made cautiously and only under medical supervision. Changing from one insulin product to another or changing the insulin strength may result in the need for a change in dosage. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. NovoLog® should be used with a longer-acting insulin. Needles, insulin pens, or syringes must not be shared.

NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

  • NovoLog® (insulin aspart [rDNA origin] injection) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

  • Administration: NovoLog® should generally be given immediately (within 5-10 minutes) prior to the start of a meal. Any change of insulin dose should be made cautiously and only under medical supervision. Changing from one insulin product to another or changing the insulin strength may result in the need for a change in dosage. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. NovoLog® should be used with a longer-acting insulin. Needles, insulin pens, or syringes must not be shared. 
  • Hypoglycemia: Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. Any change of insulin dose should be made cautiously and only under medical supervision. 
  • Hypokalemia: Insulin, particularly when given intravenously or in settings of poor glycemic control, can cause hypokalemia. Use caution in patients predisposed to hypokalemia. 
  • Renal and Hepatic Impairment: Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. 
  • Hypersensitivity and Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • Continuous Subcutaneous Insulin Infusion by External Pump: When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. 
  • Fluid retention and heart failure with concomitant use of PPAR-gamma agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age.
  • The background risk of birth defects, pregnancy loss, or other adverse events that exists for all pregnancies is increased in pregnancies complicated by hyperglycemia. 

Please click here for Prescribing Information.

 

References

  1. IMS Health Inc. IMS MIDAS. (12 months ending December 2013).
  2. Pfützner A, Reimer T, Hohberg C, Frøkjær LPF, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-2549.
  3. Data on file. Novo Nordisk, Inc., Plainsboro, NJ.
  4. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perception of pain, handling, and acceptability: A randomized, open-label, crossover study in subjects with diabetes. Diabetes Tech. 2009;11(3)195-201.